NASDAQ$KALV
KalVista Pharmaceuticals Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
KalVista provided an operational update and released financial results.
KalVista Pharmaceuticals reported no revenue for Q4 2023. The company's net loss was $26.3 million, or $(0.77) per share. Research and development expenses were $24.0 million, and general and administrative expenses were $7.8 million. The company's cash, cash equivalents and marketable securities were $149.4 million on April 30, 2023. Target enrollment was achieved for the sebetralstat phase 3 KONFIDENT trial and data readout is expected in Q4.
- Target enrollment achieved for sebetralstat phase 3 KONFIDENT trial.
- Data readout from KONFIDENT trial expected in Q4 2023.
- NDA submission planned for H1 2024.
- Company funded into 2025.
Headline financials
Revenue & EPS history
KalVista · Revenue · Quarterly
$13.7M
Forward guidance
KalVista expects data from the event-driven KONFIDENT trial in the fourth quarter of 2023 and, if successful, anticipates submitting an NDA to the FDA in the first half of 2024. With the financing, KalVista now expects to be able to fund operations into 2025.
Tailwinds
- Data readout from KONFIDENT trial expected in Q4 2023.
- NDA submission planned for H1 2024.
- Company funded into 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-0.3%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-0.7%
Avg return
30 days after
49%
21 / 43 earnings
Positive
+20.3%
Q4 2018
Best reaction
-26.3%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +1.1% | +26.3% | +56.4% | |
| Q1 2026 | -3.8% | -12.3% | -25.3% | |
| Q4 2025 | -3.1% | -5.1% | -22.4% | |
| Q3 2025 | +2.0% | -2.6% | +5.1% | |
| Q2 2025 | -4.2% | -0.2% | -4.5% | |
| Q1 2025 | -4.5% | -13.2% | -12.1% | |
| Q4 2024 | +3.7% | +21.3% | +2.6% | |
| Q3 2024 | -13.0% | -16.9% | -16.9% | |
| Q2 2024 | -9.0% | +8.8% | +26.8% | |
| Q1 2024 | -4.0% | -4.2% | -12.2% | |
| Q4 2023 | +17.0% | +7.6% | +23.5% | |
| Q3 2023 | -10.4% | -1.3% | +2.7% | |
| Q2 2023 | +9.8% | +7.3% | +27.8% | |
| Q1 2023 | +1.4% | -2.5% | -68.4% | |
| Q4 2022 | +10.6% | +18.0% | +37.5% | |
| Q3 2022 | -9.3% | -14.6% | -16.4% | |
| Q2 2022 | -0.4% | -2.9% | -4.2% | |
| Q1 2022 | -0.6% | -6.0% | -14.4% | |
| Q4 2021 | -3.0% | -2.9% | -14.0% | |
| Q3 2021 | +3.4% | +8.9% | -16.8% | |
| Q2 2021 | +5.2% | +5.1% | -7.0% | |
| Q1 2021 | +2.0% | +1.3% | +9.8% | |
| Q4 2020 | +7.2% | +4.2% | -18.8% | |
| Q3 2020 | -26.3% | -41.2% | -20.9% | |
| Q2 2020 | -1.8% | -5.7% | +18.9% | |
| Q1 2020 | +8.7% | +1.0% | -29.4% | |
| Q4 2019 | -0.5% | +1.4% | -6.7% | |
| Q3 2019 | +10.4% | +7.6% | -0.2% | |
| Q2 2019 | -14.0% | -21.2% | -15.5% | |
| Q1 2019 | +9.6% | +4.6% | +20.6% | |
| Q4 2018 | +20.3% | +29.8% | +94.0% | |
| Q3 2018 | +4.7% | +11.7% | +0.8% | |
| Q2 2018 | -4.8% | -12.3% | +0.2% | |
| Q1 2018 | -21.5% | -23.6% | +9.8% | |
| Q4 2017 | -0.8% | -2.7% | -11.6% | |
| Q3 2017 | +1.9% | -1.0% | -12.2% | |
| Q2 2017 | -1.9% | -2.9% | -1.6% | |
| Q1 2017 | +0.4% | +13.1% | -13.3% | |
| Q4 2016 | -3.2% | — | — | |
| Q3 2016 | +7.1% | — | — | |
| Q2 2016 | -3.2% | — | — | |
| Q1 2016 | +1.3% | — | — | |
| Q4 2015 | +2.4% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro